BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 10861700)

  • 1. Enhanced cell death in NR-S1 tumor by photodynamic therapy: possible involvement of Fas and Fas ligand system.
    Yokota T; Ikeda H; Inokuchi T; Sano K; Koji T
    Lasers Surg Med; 2000; 26(5):449-60. PubMed ID: 10861700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advantages of laserphyrin compared with photofrin in photodynamic therapy for bile duct carcinoma.
    Nonaka T; Nanashima A; Nonaka M; Uehara M; Isomoto H; Nonaka Y; Nagayasu T
    J Hepatobiliary Pancreat Sci; 2011 Jul; 18(4):592-600. PubMed ID: 21360081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Photodynamic therapy with hypericin induces vascular damage and apoptosis in the RIF-1 mouse tumor model.
    Chen B; Roskams T; Xu Y; Agostinis P; de Witte PA
    Int J Cancer; 2002 Mar; 98(2):284-90. PubMed ID: 11857421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fas-mediated apoptosis of melanoma cells and infiltrating lymphocytes in human malignant melanomas.
    Shukuwa T; Katayama I; Koji T
    Mod Pathol; 2002 Apr; 15(4):387-96. PubMed ID: 11950912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The evaluation of Fas/Fas ligand system in renal cell carcinoma--the effect of preoperative interferon-alpha therapy].
    Sejima T; Miyagawa I
    Nihon Hinyokika Gakkai Zasshi; 1999 Oct; 90(10):826-32. PubMed ID: 10565161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of fas/fas ligand (fasL) and its involvement in infiltrating lymphocytes in hepatocellular carcinoma (HCC).
    Fukuzawa Y; Takahashi K; Furuta K; Tagaya T; Ishikawa T; Wada K; Omoto Y; Koji T; Kakumu S
    J Gastroenterol; 2001 Oct; 36(10):681-8. PubMed ID: 11686478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fas ligand upregulation is an early event in colonic carcinogenesis.
    Bennett MW; O'Connell J; Houston A; Kelly J; O'Sullivan GC; Collins JK; Shanahan F
    J Clin Pathol; 2001 Aug; 54(8):598-604. PubMed ID: 11477113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of FasL expression in oral squamous cell cancer.
    Fang L; Sun L; Hu FF; Chen QE
    Asian Pac J Cancer Prev; 2013; 14(1):281-5. PubMed ID: 23534738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer.
    Bennett MW; O'connell J; O'sullivan GC; Roche D; Brady C; Kelly J; Collins JK; Shanahan F
    Gut; 1999 Feb; 44(2):156-62. PubMed ID: 9895372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of fas ligand in uveal melanoma-induced liver damage.
    Repp AC; Mayhew ES; Howard K; Alizadeh H; Niederkorn JY
    Graefes Arch Clin Exp Ophthalmol; 2001 Oct; 239(10):752-8. PubMed ID: 11760036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced susceptibility of mouse squamous cell carcinoma to photodynamic therapy combined with low-dose administration of cisplatin.
    Uehara M; Inokuchi T; Ikeda H
    J Oral Maxillofac Surg; 2006 Mar; 64(3):390-6. PubMed ID: 16487799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.
    Bennett MW; O'Connell J; O'Sullivan GC; Brady C; Roche D; Collins JK; Shanahan F
    J Immunol; 1998 Jun; 160(11):5669-75. PubMed ID: 9605174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia.
    Kitagawa M; Yamaguchi S; Takahashi M; Tanizawa T; Hirokawa K; Kamiyama R
    Leukemia; 1998 Apr; 12(4):486-92. PubMed ID: 9557605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape?
    Ni X; Hazarika P; Zhang C; Talpur R; Duvic M
    Clin Cancer Res; 2001 Sep; 7(9):2682-92. PubMed ID: 11555580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Action and mechanism of Fas and Fas ligand in immune escape of gallbladder carcinoma.
    Xu LN; Zou SQ; Wang JM
    World J Gastroenterol; 2005 Jun; 11(24):3719-23. PubMed ID: 15968727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of Fas/FasL expression to cell apoptosis in Epstein-Barr virus-associated gastric carcinoma.
    He D; Xiao L; Chen JN; Liang Q; Shao CK
    Chin J Cancer; 2010 Mar; 29(3):283-7. PubMed ID: 20193111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of Fas and Fas ligand in human gastric adenomas and intestinal-type carcinomas: correlation with proliferation and apoptosis.
    Osaki M; Kase S; Kodani I; Watanabe M; Adachi H; Ito H
    Gastric Cancer; 2001; 4(4):198-205. PubMed ID: 11846063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical characterization of Fas (CD95) and Fas Ligand (FasL/CD95L) expression in the injured brain: relationship with neuronal cell death and inflammatory mediators.
    Grosjean MB; Lenzlinger PM; Stahel PF; Yatsiv I; Shohami E; Trentz O; Kossmann T; Morganti-Kossmann MC
    Histol Histopathol; 2007 Mar; 22(3):235-50. PubMed ID: 17163398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of Fas/Fas ligand in the induction of apoptosis in chronic sialadenitis of minor salivary glands including Sjögren's syndrome.
    Shibata Y; Hishikawa Y; Izumi S; Fujita S; Yamaguchi A; Koji T
    Hum Cell; 2002 Mar; 15(1):52-60. PubMed ID: 12126064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible role of Fas/Fas ligand-mediated apoptosis in the pathogenesis of fixed drug eruption.
    Choi HJ; Ku JK; Kim MY; Kang H; Cho SH; Kim HO; Park YM
    Br J Dermatol; 2006 Mar; 154(3):419-25. PubMed ID: 16445769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.